Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 4Completed 1

Sponsor Class

OTHER 843NIH 197INDUSTRY 150NETWORK 139OTHER_GOV 10UNKNOWN 5FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Radiation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
UNKNOWN × Etoposide × Clear all
NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04683198 2020-12-24

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

ChineseAMS

Phase 2 Unknown
69 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
32 enrolled
Breast

Breast Neoplasms

NCT02323737 2014-12-30

Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer

ChineseAMS

Phase 2 Completed
62 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01492556 2013-03-15

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

ChineseAMS

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡